サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1422854

免疫チェックポイント阻害薬市場レポート：タイプ別、流通チャネル別、用途別、地域別、2024-2032年

Immune Checkpoint Inhibitors Market Report by Type, Distribution Channel, Application, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 145 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
免疫チェックポイント阻害薬市場レポート：タイプ別、流通チャネル別、用途別、地域別、2024-2032年
出版日: 2024年01月30日
発行: IMARC
ページ情報: 英文 145 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

免疫チェックポイント阻害薬の世界市場規模は2023年に431億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに1,572億米ドルに達し、2024～2032年の成長率（CAGR）は15.01%になると予測しています。さまざまながんの有病率の上昇、呼吸器疾患の増加、個別化医療への嗜好の高まりが、市場を牽引する主な要因のひとつです。

免疫チェックポイント阻害薬は、T細胞やがん細胞などの免疫系細胞によって作られる特定のタンパク質を阻害することで、がんの治療に利用される薬剤です。単独で、あるいは化学療法や放射線療法など他のがん治療と組み合わせて使用され、治療効果を高める。免疫チェックポイント阻害薬は、病気の症状を軽減し、生存期間を延長することで、がん患者の生活の質を高めるのに役立ちます。免疫チェックポイント阻害薬は、免疫系の特定の経路を標的とするため、がん治療により的を絞ったアプローチが可能となります。これらの阻害薬は、従来の化学療法と比較して、副作用が少なく、患者の忍容性を高める低毒性プロファイルを持っています。現在、がん細胞内の特定の遺伝子変異の同定を可能にする次世代シーケンシング技術の利用が増加しており、これが世界中で免疫チェックポイント阻害薬の需要を喚起しています。

免疫チェックポイント阻害薬の市場動向：

メラノーマ、肝臓がん、腎臓がん、胃がんなど、さまざまながんの罹患率が急増していることは、免疫チェックポイント阻害薬の需要を世界中で押し上げている主な要因のひとつです。さらに、このような重篤ながんを発症しやすい高齢化人口の増加や肥満の有病率の上昇が、市場の成長を後押ししています。さらに、アルコール飲料やタバコの消費量の増加により、呼吸器疾患の発生率が増加しています。このことは、不健康な食習慣や座りがちなライフスタイルのために体重に関連した健康上の懸念が増加していることと相まって、市場にプラスの影響を与えています。これとは別に、さまざまな遺伝性疾患や生活習慣病の急増、がんの早期診断と治療の利点に関する個人や医療専門家の意識の高まりが、市場の成長を後押ししています。さらに、製薬企業による臨床試験の拡大、個別化医薬品や新世代の医薬品・製剤に対する嗜好の高まりが、市場の成長を後押ししています。これに加えて、製品ポートフォリオを拡大し競合優位性を獲得するために、大手企業が戦略的提携や新製品開拓に注力する傾向が強まっていることも、市場に明るい展望をもたらしています。さらに、医療インフラと診断技術の大幅な向上が市場の成長を強化すると予測されています。

本レポートで扱う主な質問

  • 免疫チェックポイント阻害薬の世界市場規模は？
  • 2024年から2032年にかけての免疫チェックポイント阻害薬世界市場の予想成長率は？
  • 免疫チェックポイント阻害薬の世界市場を牽引する主要因は何か？
  • COVID-19が免疫チェックポイント阻害薬の世界市場に与えた影響は？
  • 免疫チェックポイント阻害薬の世界市場におけるタイプ別の区分は？
  • 免疫チェックポイント阻害薬の世界市場における販売チャネル別の内訳は？
  • 免疫チェックポイント阻害薬の世界市場の用途別区分は？
  • 免疫チェックポイント阻害薬の世界市場における主要地域は？
  • 免疫チェックポイント阻害薬の世界市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 免疫チェックポイント阻害薬の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • CTLA-4阻害薬
    • 市場動向
    • 市場予測
  • PD-1阻害薬
    • 市場動向
    • 市場予測
  • PD-L1阻害薬
    • 市場動向
    • 市場予測

第7章 市場内訳：流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • 小売薬局
    • 市場動向
    • 市場予測
  • オンライン薬局
    • 市場動向
    • 市場予測

第8章 市場内訳：用途別

  • 肺がん
    • 市場動向
    • 市場予測
  • 膀胱がん
    • 市場動向
    • 市場予測
  • メラノーマ
    • 市場動向
    • 市場予測
  • 大腸がん
    • 市場動向
    • 市場予測
  • ホジキンリンパ腫
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 促進要因、抑制要因、機会

  • 市場概要
  • 促進要因
  • 抑制要因
  • 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • GSK plc
    • Merck & Co. Inc.
    • Ono Pharmaceutical Co. Ltd.
    • Pfizer Inc.
    • Regeneron Pharmaceuticals Inc.
    • Seagen Inc.
図表

List of Figures

  • Figure 1: Global: Immune Checkpoint Inhibitors Market: Major Drivers and Challenges
  • Figure 2: Global: Immune Checkpoint Inhibitors Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Immune Checkpoint Inhibitors Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Immune Checkpoint Inhibitors Market: Breakup by Distribution Channel (in %), 2023
  • Figure 6: Global: Immune Checkpoint Inhibitors Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Immune Checkpoint Inhibitors Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Immune Checkpoint Inhibitors (CTLA-4 Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Immune Checkpoint Inhibitors (CTLA-4 Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Immune Checkpoint Inhibitors (PD-1 Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Immune Checkpoint Inhibitors (PD-1 Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Immune Checkpoint Inhibitors (PD-L1 Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Immune Checkpoint Inhibitors (PD-L1 Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Immune Checkpoint Inhibitors (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Immune Checkpoint Inhibitors (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Immune Checkpoint Inhibitors (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Immune Checkpoint Inhibitors (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Immune Checkpoint Inhibitors (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Immune Checkpoint Inhibitors (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Immune Checkpoint Inhibitors (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Immune Checkpoint Inhibitors (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Immune Checkpoint Inhibitors (Bladder Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Immune Checkpoint Inhibitors (Bladder Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Immune Checkpoint Inhibitors (Melanoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Immune Checkpoint Inhibitors (Melanoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Immune Checkpoint Inhibitors (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Immune Checkpoint Inhibitors (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Immune Checkpoint Inhibitors (Hodgkin Lymphoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Immune Checkpoint Inhibitors (Hodgkin Lymphoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Immune Checkpoint Inhibitors (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Immune Checkpoint Inhibitors (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: North America: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: North America: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: United States: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: United States: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Canada: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Canada: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Asia-Pacific: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Asia-Pacific: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: China: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: China: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Japan: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Japan: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: India: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: India: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: South Korea: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: South Korea: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Australia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Australia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Indonesia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Indonesia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Europe: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Europe: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Germany: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Germany: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: France: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: France: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: United Kingdom: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: United Kingdom: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Italy: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Italy: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Spain: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Spain: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Russia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Russia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Latin America: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Latin America: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Brazil: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Brazil: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Mexico: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Mexico: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Middle East and Africa: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Middle East and Africa: Immune Checkpoint Inhibitors Market: Breakup by Country (in %), 2023
  • Figure 80: Middle East and Africa: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Global: Immune Checkpoint Inhibitors Industry: Drivers, Restraints, and Opportunities
  • Figure 82: Global: Immune Checkpoint Inhibitors Industry: Value Chain Analysis
  • Figure 83: Global: Immune Checkpoint Inhibitors Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Immune Checkpoint Inhibitors Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 4: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Immune Checkpoint Inhibitors Market: Competitive Structure
  • Table 7: Global: Immune Checkpoint Inhibitors Market: Key Players
目次
Product Code: SR112024A7221

Abstract

The global immune checkpoint inhibitors market size reached US$ 43.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 157.2 Billion by 2032, exhibiting a growth rate (CAGR) of 15.01% during 2024-2032. The rising prevalence of various cancers, increasing incidences of respiratory disorders, and the growing preference for personalized medicines represent some of the key factors driving the market.

Immune checkpoint inhibitors are drugs utilized for treating cancer by inhibiting specific proteins made by immune system cells, such as T cells and cancer cells. They are either used alone or in combination with other cancer treatments, such as chemotherapy and radiation therapy to enhance treatment outcomes. They aid in enhancing the quality of life for cancer patients by reducing the symptoms of the disease and extending their survival. Immune checkpoint inhibitors target specific pathways in the immune system, which enables a more targeted approach to cancer treatment. These inhibitors have a lower toxicity profile that leads to fewer side effects and better tolerance to patients as compared to traditional chemotherapy. At present, the rising use of next-generation sequencing technologies that enables the identification of specific genetic mutations in cancer cells is catalyzing the demand for immune checkpoint inhibitors across the globe.

Immune Checkpoint Inhibitors Market Trends:

The surging prevalence of various cancers among individuals, such as melanoma, liver, kidney, and gastric, represents one of the major factors driving the demand for immune checkpoint inhibitors around the world. Moreover, the increasing aging population, which is more prone to develop such severe cancers and the rising prevalence of obesity is favoring the market growth. In addition, there is an increase in the incidences of respiratory disorders on account of the rising consumption of alcoholic beverages and tobacco-based products. This, coupled with the growing numbers of weight-related health concerns on account of unhealthy eating habits and sedentary lifestyles, is influencing the market positively. Apart from this, the surging occurrence of various genetic and lifestyle diseases and the increasing awareness among individuals and healthcare professionals about the benefits of early diagnosis and treatment of cancer is propelling the growth of the market. Furthermore, the expanding number of clinical trials by pharmaceutical companies and the rising preference for personalized medicines and new generation drugs and formulations are propelling the growth of the market. Besides this, the growing focus of leading players on strategic collaborations and new product developments to expand their product portfolio and gain a competitive edge is creating a positive outlook for the market. Additionally, significant improvements in medical infrastructure and diagnostic technologies are anticipated to strengthen the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global immune checkpoint inhibitors market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on type, distribution channel, and application.

Type Insights:

CTLA-4 Inhibitor

PD-1 Inhibitor

PD-L1 Inhibitor

The report has provided a detailed breakup and analysis of the immune checkpoint inhibitors market based on the type. This includes CTLA-4 inhibitor, PD-1 inhibitor, and PD-L1 inhibitor. According to the report, PD-1 inhibitor represented the largest segment.

Distribution Channel Insights:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

A detailed breakup and analysis of the immune checkpoint inhibitors market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.

Application Insights:

Lung Cancer

Bladder Cancer

Melanoma

Colorectal Cancer

Hodgkin Lymphoma

Others

The report has provided a detailed breakup and analysis of the immune checkpoint inhibitors market based on the application. This includes lung cancer, bladder cancer, melanoma, colorectal cancer, Hodgkin lymphoma, and others. According to the report, lung cancer represented the largest segment.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for immune checkpoint inhibitors. Some of the factors driving the North America immune checkpoint inhibitors market included the increasing aging population, presence of a well-established healthcare infrastructure, rising research and development (R&D) activities, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global immune checkpoint inhibitors market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Seagen Inc., etc.

Key Questions Answered in This Report

  • 1. How big is the global immune checkpoint inhibitors market?
  • 2. What is the expected growth rate of the global immune checkpoint inhibitors market during 2024-2032?
  • 3. What are the key factors driving the global immune checkpoint inhibitors market?
  • 4. What has been the impact of COVID-19 on the global immune checkpoint inhibitors market?
  • 5. What is the breakup of the global immune checkpoint inhibitors market based on the type?
  • 6. What is the breakup of the global immune checkpoint inhibitors market based on the distribution channel?
  • 7. What is the breakup of the global immune checkpoint inhibitors market based on the application?
  • 8. What are the key regions in the global immune checkpoint inhibitors market?
  • 9. Who are the key players/companies in the global immune checkpoint inhibitors market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Immune Checkpoint Inhibitors Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 CTLA-4 Inhibitor
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 PD-1 Inhibitor
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 PD-L1 Inhibitor
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Pharmacies
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Lung Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Bladder Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Melanoma
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Colorectal Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Hodgkin Lymphoma
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AstraZeneca plc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bristol-Myers Squibb Company
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 GSK plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Merck & Co. Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Ono Pharmaceutical Co. Ltd.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Pfizer Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Regeneron Pharmaceuticals Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Seagen Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis